During the past decade, Institute for Cardiovascular Diseases Dedinje conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 2 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 2 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institute for Cardiovascular Diseases Dedinje" #1 sponsor was "Università Vita-Salute San Raffaele" with 3 trials, followed by "Boehringer Ingelheim" with 2 trials sponsored, "Arena Pharmaceuticals" with 1 trials sponsored, "AstraZeneca" with 1 trials sponsored and "Berlin Heals GmbH" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institute for Cardiovascular Diseases Dedinje" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator, "ICON plc" with 1 trials as a collaborator, "Medidata Solutions" with 1 trials as a collaborator and "PPD" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Institute for Cardiovascular Diseases Dedinje" are "ACS (Acute Coronary Syndrome)" (1 trials), "Acute Heart Failure With Reduced Ejection Fraction" (1 trials), "Aorto-Iliac Occlusive Disease" (1 trials), "Aortocoronary Bypass" (1 trials) and "Aortoiliac Aneurysms" (1 trials). Many other conditions were trialed in "Institute for Cardiovascular Diseases Dedinje" in a lesser frequency.

Most popular intervention types in "Institute for Cardiovascular Diseases Dedinje" are "Drug" (6 trials), "Device" (3 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "APD418" (1 trials), "Acute normovolemic hemodilution" (1 trials), "Apabetalone" (1 trials) and "Atorvastatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institute for Cardiovascular Diseases Dedinje" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Institute for Cardiovascular Diseases Dedinje". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Institute for Cardiovascular Diseases Dedinje, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Institute for Cardiovascular Diseases Dedinje, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 4 trials that are defined as “Not Applicable".